BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

Intellia Therapeutics, Inc. (NTLA), a clinical-stage gene editing company, Monday said that the U.S. Food and Drug Administration or ...

This Friday, local man David Tasker will complete the last of his ten challenges to raise money for amyloidosis research and ...

Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...

Ultromics Ltd. received clearance from the U.S. FDA for Echogo Amyloidosis, its artificial intelligence-enhanced software that helps with the early diagnosis of cardiac amyloidosis, enabling timely ...

Ultromics' EchoGo® Amyloidosis, clinical AI for echocardiography with the potential to revolutionize early detection of ...

Shares of biotech Intellia Therapeutics ( NTLA 5.18%) are down by around 33% over the past 30 days, amid the publication of ...

The study showed significant reductions in serum TTR levels in subjects after a single dose, with sustained effects over time ...

The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...

Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months ...

The US Food and Drug Administration (FDA) on Friday approved Attruby (acoramidis), an orally-administered near-complete (≥90% ...